<?xml version="1.0" encoding="UTF-8"?>
<p id="Par7">In February 2019, CEPI agreed to provide up to $34 million in support of CureVac’s technology development, which will provide a rapid supply of lipid-nanoparticle-formulated mRNA vaccine candidates that can target known pathogens and prepare for rapid response to new and previously unknown pathogens. The principle of CureVac’s proprietary technology is the use of mRNA as a genetic information carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. Additionally, the Federal Ministry of Education and Research has committed a total of 90 million Euros to support this work (Smith 
 <xref ref-type="bibr" rid="CR12">2020</xref>).
</p>
